Stein Singh
Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis, poses significant challenges in management due to its chronic and relapsing nature. Fecal Microbiota Transplantation (FMT) has emerged as a promising therapeutic option, aiming to restore the dysbiotic gut microbiota associated with IBD. This review explores the importance of FMT in managing IBD by examining its mechanisms of action, clinical efficacy, safety profile and future directions. Evidence from preclinical studies, clinical trials and real-world experiences is synthesized to elucidate the role of FMT in inducing remission, reducing disease activity and improving quality of life in IBD patients. Moreover, considerations such as donor selection, delivery methods and long-term outcomes are discussed to optimize the implementation of FMT in clinical practice. Overall, FMT holds immense potential as a safe and effective adjunctive therapy for IBD, offering novel insights into the interplay between the gut microbiota and host immune system.
इस लेख का हिस्सा
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu 